April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […] READ MORE
April 14, 2021 Dr. Boris Reizis and his team, working with a group of clinical rheumatologists led by Dr. Jill Buyon, have made a connection between an enzyme that prevents people’s immune systems from reacting to their own DNA and lupus activity. In a paper just published in the Journal of Experimental Medicine they report […] READ MORE
Monday, May 3, 2021 – The Willie Colon Golf Outing benefiting the Lupus Research Alliance Jean Davis Research Grant looks to once again raise thousands of dollars in crucial funds for lupus research programs — while increasing awareness of the disease. Held at the Canoe Brook Country Club in Summit, NJ, the Outing is the […] READ MORE
April 8, 2021 In honor of National Siblings Day, we’re bringing you the story of TwoBeingHealthy — two sisters and strong social media voices – Kate (30) and Em (33) – who are so close they seem almost like twins. They went to the same college, live together in Seattle, hang out with the same […] READ MORE
March 31, 2021 As part of the LRA’s mission to accelerate development and availability of much-needed new diagnostics and treatments for lupus, the organization’s President and CEO, Mr. Kenneth M. Farber, submitted a letter to President Joseph Biden to express LRA’s strong support for Dr. Janet Woodcock to be nominated for Commissioner of the U.S. […] READ MORE
Dr. Eric Morand Publishes Results Funded by LRA’s Distinguished Innovator Award NEW YORK, NY. March 31, 2021. Results of critical work funded by the Lupus Research Alliance Distinguished Innovator Award to Dr. Eric Morand suggests a path toward making lupus treatment with glucocorticoids (steroids) effective at lower doses, lessening harmful side effects. In a study […] READ MORE
March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE). This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […] READ MORE
March 29, 2021 Patients with lupus are more likely to have metabolic syndrome and insulin resistance – both factors linked to heart disease – if they have lower vitamin D levels, a new study reveals. Researchers believe that boosting vitamin D levels may improve control of these cardiovascular risk factors, as well as improving long-term […] READ MORE
NEW YORK, March 25, 2021 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2020 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Jacques Banchereau, PhD and Ignacio Sanz, MD. Both projects funded by this grant are investigating different mechanisms altered in lupus patients that induce an autoimmune response. Their findings […] READ MORE
Join LRA’s Interactive, Virtual Lupus Clinical Trials Fair on April 8th! · Learn more about an upcoming study LRA is doing on COVID-19 vaccines in people with lupus · Network and talk to people who’ve been in a lupus trial · Speak with the researchers conducting lupus trials near you · Compete for prizes…and MUCH MORE Click here to […] READ MORE
March 19, 2021 Ten new applications for promising scientific studies were just recommended for funding by the Lupus Research Program (LRP) within the Department of Defense! The dedicated Lupus Research Program was first established in 2017 under the Congressionally Directed Medical Research Programs operated by the Army Medical Research and Materiel Command in Ft. Detrick, […] READ MORE
March 17, 2021 People with systemic lupus erythematosus (SLE) are at risk for cardiovascular diseases, and those with lupus nephritis are at greater risk, according to the findings of a new analysis of 20 clinical studies. Results showed that people with SLE are twice as likely to develop cardiovascular disease as healthy people. Their risk […] READ MORE
